ConductScience.org, home

Paper168385

Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Arcamone F and 10 others. J Med Chem, 1975. Cited by 180 papers, by iCite.

Cite this record

ConductScience Library. Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. Papers, record 168385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/168385

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.
PubMed
Journal
J Med Chem
PubMed
Year
1975
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
180
iCite
Relative citation ratio, by iCite
6.87
iCite
Revised in PubMed
2019-07-09
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Arcamone FF
2Penco SS
3Vigevani AA
4Redaelli SS
5Franchi GG
6DiMarco AA
7Casazza AMA M
8Dasdia TT
9Formelli FF
10Necco AA
11Soranzo CC

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AminoglycosidesMajor topic
Antineoplastic AgentsMajor topic
DaunorubicinMajor topic
DoxorubicinMajor topic
Animals
Cells, Cultured
HeLa Cells
Heart Rate
In Vitro Techniques
Leukemia, Experimental
Mice
Moloney murine leukemia virus
Sarcoma 180
Sarcoma Viruses, Murine
Stereoisomerism

Source PubMed

Download CSV of topics

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 180 citations.

PMIDTitleJournalYearIn PapersSource
38474678Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation.Molecules2024https://conductscience.org/library/papers/38474678PubMed
31511390Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.J Virol2019https://conductscience.org/library/papers/31511390PubMed
24105928Synthesis of vicinal aminoalcohols by stereoselective aza-Wacker cyclizations: access to (-)-acosamine by redox relay.Angew Chem Int Ed Engl2013https://conductscience.org/library/papers/24105928PubMed
21705665TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.Oncologist2011https://conductscience.org/library/papers/21705665PubMed
21375717Natural products for cancer chemotherapy.Microb Biotechnol2011https://conductscience.org/library/papers/21375717PubMed
20424853Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.Histochem Cell Biol2010https://conductscience.org/library/papers/20424853PubMed
8070217Clinical pharmacokinetics of epirubicin.Clin Pharmacokinet1994https://conductscience.org/library/papers/8070217PubMed
7693418Epirubicin. Clinical pharmacology and dose-effect relationship.Drugs1993https://conductscience.org/library/papers/7693418PubMed
6595241Phase II study of epirubicin in advanced malignant melanoma.Invest New Drugs1984https://conductscience.org/library/papers/6595241PubMed
6590532Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors.Invest New Drugs1983https://conductscience.org/library/papers/6590532PubMed
6584236A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6584236PubMed
65832054'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors.J Cancer Res Clin Oncol1984https://conductscience.org/library/papers/6583205PubMed
6579052Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.J Cancer Res Clin Oncol1983https://conductscience.org/library/papers/6579052PubMed
6378238Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.Br J Cancer1984https://conductscience.org/library/papers/6378238PubMed
3886588The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.Invest New Drugs1985https://conductscience.org/library/papers/3886588PubMed
3863718Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3863718PubMed
3857219Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).Invest New Drugs1985https://conductscience.org/library/papers/3857219PubMed
3520474Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.Pharm Weekbl Sci1986https://conductscience.org/library/papers/3520474PubMed
3472675Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3472675PubMed
3463434Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3463434PubMed

See all 34 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/168385

GET https://conductscience.org/api/papers/v1/168385/cited_by?page=2